论文部分内容阅读
随着心律失常电生理的研究进展,近年来治疗心律失常药物有了较快的发展,对心血管病的防治提供了有力的武器。现将抗心律失常药物的新进展和初步临床评价作一综述。一、治疗心律失常药物电生理分类 Arnsdorf根据心肌细胞电生理,将抗心律失常药物分为五类: 1.抑制Na~+通道药物:以奎尼丁为代表,包括普鲁卡因酰胺、双异丙吡胺(Disopyramide)常咯啉等。其电生理作用:①降低膜对Na~+的通透性,降低0相上升速度和幅度;②减慢传导速度;③变单向阻滞为双向阻滞,从而可消除由折返引起的心律失常;④抑制4相Na~+流入,使4相坡度变平,能消除自律性增高引起的心律失常。临床应用时对室上性和室性心律失常都有效。
With the progress of electrophysiological study of arrhythmia, the rapid development of arrhythmia drugs in recent years has provided a powerful weapon for the prevention and treatment of cardiovascular diseases. Now the new progress of anti-arrhythmic drugs and preliminary clinical evaluation are reviewed. First, the treatment of arrhythmic drugs Electrophysiological classification Arnsdorf According to myocardial electrophysiology, anti-arrhythmic drugs are divided into five categories: 1. Inhibition of Na ~ + channel drugs: quinidine as the representative, including procainamide, bis Disopyramide, and the like. Its electrophysiological effects: ① reduce membrane permeability of Na ~ +, reduce the rate and amplitude of 0 phase rise; ② slow down the conduction velocity; ③ change unidirectional block is a two-way block, which can eliminate the reentry-induced heart rhythm Disorders; ④ inhibit the 4-phase Na ~ + influx, 4-phase slope flattening, can eliminate self-discipline caused by increased arrhythmia. Clinical application of supraventricular and ventricular arrhythmias are valid.